19 -10 (84) 2025 - Xayitov D.X., Khakimov B.A. - MODERN APPROACHES TO THE SELECTION AND DURATION OF DUAL ANTIPLATELET THERAPY AFTER PERCUTANEOUS CORONARY INTERVENTION IN ACUTE CORONARY SYNDROME

MODERN APPROACHES TO THE SELECTION AND DURATION OF DUAL ANTIPLATELET THERAPY AFTER PERCUTANEOUS CORONARY INTERVENTION IN ACUTE CORONARY SYNDROME

Xayitov D.X. - Bukhara State Medical Institute named after Abu Ali ibn Sina

Khakimov B.A. - Bukhara State Medical Institute named after Abu Ali ibn Sina

Resume

Current literature data indicate the appropriateness of individualizing antiplatelet therapy in patients with acute myocardial infarction after coronary artery stenting, particularly in those with a high risk of bleeding complications. One randomized clinical trial [1] demonstrated that shortening the duration of dual antiplatelet therapy (DAPT) to one month followed by P2Y₁₂ inhibitor monotherapy does not increase the incidence of ischemic events but significantly reduces the risk of major bleeding. Similar conclusions were confirmed in the SHARP-MI registry [2], where early discontinuation of DAPT (after ≥1 month) showed comparable clinical efficacy to the standard 12-month regimen. Furthermore, another study [3] reported that switching to prasugrel monotherapy three months after percutaneous coronary intervention reduces both the rate of major bleeding and the overall incidence of adverse clinical outcomes. These findings support the relevance of personalized and adaptive DAPT strategies aimed at optimizing the balance between thrombotic and hemorrhagic risks in patients after acute coronary syndrome and stenting.

Keywords: acute myocardial infarction, dual antiplatelet therapy, coronary artery stenting, bleeding risk, P2Y₁₂ inhibitors, prasugrel.

First page

103

Last page

106

For citation:Xayitov D.X., Khakimov B.A. - MODERN APPROACHES TO THE SELECTION AND DURATION OF DUAL ANTIPLATELET THERAPY AFTER PERCUTANEOUS CORONARY INTERVENTION IN ACUTE CORONARY SYNDROME//New Day in Medicine 10(84)2025 103-106 https://newdayworldmedicine.com/en/new_day_medicine/10-84-2025

List of References

1. Smits PC et al., «Abbreviated Antiplatelet Therapy After Coronary Stenting in Patients With Myocardial Infarction at High Bleeding Risk», 2022; 1220-1237 pp.
2. Hakansson A et al., «Abbreviated Versus Standard Dual Antiplatelet Therapy Times After PCI in Patients With High Bleeding Risk With Acute Coronary Syndrome», 2024; e034709 pp.
3. Lee Y‑J et al., «Ticagrelor Monotherapy After 3-Month Dual Antiplatelet Therapy in Acute Coronary Syndrome by High Bleeding Risk», 2022; 324-337 pp.
4. An J., «Shortening the Duration of Dual Antiplatelet Therapy in Patients with Acute Coronary Syndrome Undergoing PCI», 2022; 101-114 pp.
5. Sibbing D. et al., «Guided De-Escalation of Antiplatelet Treatment in Patients With Acute Coronary Syndrome Undergoing PCI (TROPICAL-ACS)», 2017; 1747-1757 pp.
6. Mehran R. et al. «Ticagrelor with or without Aspirin in High-Risk Patients After PCI (TWILIGHT)», 2019; 2032-2042 pp.

   file

   download